- Home
- CRNX vs TGTX Comparison
CRNX vs TGTX Comparison
Compare CRNX & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- TGTX
- Stock Information
- Founded
- CRNX 2008
- TGTX 1993
- Country
- CRNX United States
- TGTX United States
- Employees
- CRNX N/A
- TGTX N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- CRNX Health Care
- TGTX Health Care
- Exchange
- CRNX Nasdaq
- TGTX Nasdaq
- Market Cap
- CRNX 5.2B
- TGTX 5.4B
- IPO Year
- CRNX 2018
- TGTX 1995
- Fundamental
- Price
- CRNX $54.66
- TGTX $33.36
- Analyst Decision
- CRNX Strong Buy
- TGTX Strong Buy
- Analyst Count
- CRNX 10
- TGTX 6
- Target Price
- CRNX $74.40
- TGTX $40.67
- AVG Volume (30 Days)
- CRNX 594.1K
- TGTX 2.3M
- Earning Date
- CRNX 11-12-2024
- TGTX 11-04-2024
- Dividend Yield
- CRNX N/A
- TGTX N/A
- EPS Growth
- CRNX N/A
- TGTX N/A
- EPS
- CRNX N/A
- TGTX N/A
- Revenue
- CRNX $1,038,999.00
- TGTX $264,790,000.00
- Revenue This Year
- CRNX N/A
- TGTX $43.74
- Revenue Next Year
- CRNX $195.21
- TGTX $64.30
- P/E Ratio
- CRNX N/A
- TGTX N/A
- Revenue Growth
- CRNX N/A
- TGTX 39.53
- 52 Week Low
- CRNX $33.67
- TGTX $12.84
- 52 Week High
- CRNX $62.53
- TGTX $36.84
- Technical
- Relative Strength Index (RSI)
- CRNX 45.55
- TGTX 55.20
- Support Level
- CRNX $52.85
- TGTX $30.41
- Resistance Level
- CRNX $56.15
- TGTX $35.03
- Average True Range (ATR)
- CRNX 2.36
- TGTX 1.55
- MACD
- CRNX -0.32
- TGTX -0.33
- Stochastic Oscillator
- CRNX 29.91
- TGTX 51.78
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.